Reaction

Therapeutic Product Ineffective reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,870 reports · 59 co-occurring drugs

As of the last recalculation, Therapeutic Product Ineffective appears in 3,870 FAERS reports alongside 59 co-occurring drug terms. The strongest observed disproportionality signal is METHYLPHENIDATE (PRR 24.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Methylphenidate	129	24.8	24.9
Asenapine Maleate	27	16.9	16.9
Regorafenib	26	12.1	12.1
Rotigotine	30	11.2	11.3
Buprenorphine Hydrochloride, Naloxone Hydrochloride	44	9.9	9.9
Estradiol Gel 0.1%	80	9.7	9.7
Estradiol Transdermal	80	9.7	9.7
Daspone	17	9.4	9.4
Dapsone Gel, 5%	17	9.4	9.4
Dapsone	18	9.1	9.1
Interferon Beta-1B	29	8.2	8.2
Albuterol Sulfate	385	7.6	7.6
Loratadine And Pseudoephedrine Sulfate	11	7.5	7.5
Estradiol	116	7.4	7.4
Paroxetine Hydrochloride Hemihydrate	42	6.8	6.9
Crisaborole	12	6.7	6.8
Paroxetine	42	6.7	6.7
Guanfacine	9	6.2	6.2
Amitriptyline Hydrochloride	20	6.2	6.2
Fluticasone Furoate	13	5.8	5.8
Ketoconazole Foam	15	5.5	5.5
Ketoconazole Cream, 2%	15	5.5	5.5
Peginterferon Alfa-2A	52	5.2	5.2
Ketoconazole	16	5.0	5.0
Quetiapine Fumarate	24	4.4	4.4
Mirtazapine	71	4.2	4.2
Lanreotide Acetate	6	4.1	4.1
Sorafenib	15	3.9	3.9
Loratadine Tablet	38	3.8	3.8
Secukinumab	110	3.7	3.7
Clobetasol Propionate Ointment Usp, 0.05%	7	3.7	3.7
Clobetasol Propionate	7	3.6	3.6
Tramadol Hydrochloride	25	3.6	3.6
Progesterone	15	3.5	3.5
Heparin Sodium	9	3.5	3.5
Polyethylene Glycol 3350	59	3.4	3.4
Azelastine	11	3.3	3.3
Naproxen Sodium Tablet, Coated	8	3.2	3.2
Naproxen Sodium, Coated Tablets	8	3.2	3.2
Naproxen Sodium 220Mg	8	3.2	3.2
Lacosamide	21	3.0	3.0
Paliperidone	13	3.0	3.0
Ribavirin	34	2.9	2.9
Erlotinib	5	2.8	2.8
Aflibercept	16	2.8	2.8
Timolol	6	2.7	2.7
Selinexor	4	2.5	2.5
Brivaracetam	4	2.4	2.4
Vilazodone Hydrochloride	4	2.3	2.3
Benralizumab	8	2.2	2.2
Erlotinib Hydrochloride	5	2.2	2.2
Romosozumab-Aqqg	5	2.0	2.0
Ixekizumab	12	1.7	1.7
Isotretinoin	16	1.7	1.7
Sofosbuvir	6	1.6	1.6
Ranibizumab	8	1.6	1.6
Esketamine Hydrochloride	5	1.5	1.5
Etonogestrel	10	1.1	1.1
Guselkumab	7	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.